



available at www.sciencedirect.com

Clinical Immunology

www.elsevier.com/locate/yclim



REVIEW

Monogenic autoinflammatory diseases: Concept and clinical manifestations



Adriana Almeida de Jesus, Raphaela Goldbach-Mansky*

Translational Autoinflammatory Diseases Section, National Institute of Arthritis, Musculoskeletal and Skin diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, USA

Received 1 March 2013; accepted with revision 30 March 2013

Available online 9 April 2013

KEYWORDS

Autoinflammatory diseases;
CAPS;
FMF;
TRAPS;
HIDS;

Abstract The objective of this review is to describe the clinical manifestations of the growing spectrum of monogenic autoinflammatory diseases including recently described syndromes. The autoinflammatory diseases can be grouped based on clinical findings: 1. the three classic hereditary “periodic fever syndromes”, familial Mediterranean Fever (FMF); TNF receptor associated periodic syndrome (TRAPS); and mevalonate kinase deficiency/hyperimmunoglobulinemia D and periodic fever syndrome (HIDS); 2. the cryopyrin associated periodic syndromes (CAPS), comprising familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID) or CINCA, and; 3. pediatric granulomatous arthritis (PGA); 4. disorders presenting with skin pustules, including deficiency of interleukin 1 receptor antagonist (DIRA); Majeed syndrome; pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome; deficiency of interleukin 36 receptor antagonist (DITRA); *CARD14* mediated psoriasis (CAMPs), and early-onset inflammatory bowel diseases (EO-IBD); 5. inflammatory disorders caused by mutations in proteasome components, the proteasome associated autoinflammatory syndromes (PRAAS) and 6. very rare conditions presenting with autoinflammation and immunodeficiency.

Published by Elsevier Inc.

Contents

1. Introduction	156
2. The classic “periodic fever syndromes” presenting with recurrent episodic fevers, non-specific maculopapular rashes and abdominal pain	158
2.1. Familial Mediterranean fever (FMF)	158
2.1.1. Epidemiology and genetics	158
2.1.2. Clinical presentation and diagnosis	158
2.1.3. Treatment	159

* Corresponding author at: Translational Autoinflammatory Diseases Section, National Institute of Arthritis, Musculoskeletal and Skin diseases (NIAMS), Clinical Center, National Institutes of Health (NIH), Bldg. 10, Room 6D47-B, 10 Center Drive, Bethesda, MD 20814, USA. Fax: +1 301 402 1884.
E-mail address: goldbacr@mail.nih.gov (R. Goldbach-Mansky).

2.2.	Mevalonate kinase deficiency/hyperimmunoglobulinemia D with periodic fever syndrome (HIDS)	159
2.2.1.	Epidemiology and genetics	159
2.2.2.	Clinical presentation and diagnosis	159
2.2.3.	Treatment	159
2.3.	TNF receptor associated periodic syndrome (TRAPS)	160
2.3.1.	Epidemiology and genetics	160
2.3.2.	Clinical presentation and diagnosis	160
2.3.3.	Treatment	160
3.	Syndromes presenting with neutrophilic urticaria (the cryopyrinopathies)	160
3.1.	Epidemiology and genetics	160
3.2.	Clinical presentation and diagnosis	161
3.3.	Familial cold autoinflammatory syndrome (FCAS)	162
3.4.	Muckle–Wells syndrome (MWS)	162
3.5.	Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic cutaneous and articular syndrome (CINCA)	162
3.5.1.	Treatment of CAPS	163
4.	Syndromes presenting with granulomatous skin lesions and minimal or low-grade fever attacks	163
4.1.	Blau syndrome/early onset sarcoidosis (pediatric granulomatous arthritis)	163
4.1.1.	Epidemiology and genetics	163
4.1.2.	Clinical presentation and diagnosis	163
4.1.3.	Treatment	163
5.	Syndromes presenting with pustular skin rashes and episodic or continuous fever	163
5.1.	With inflammatory bone disease	163
5.1.1.	Deficiency of interleukin 1 receptor antagonist (DIRA)	163
5.1.2.	Majeed syndrome	164
5.2.	With pyogenic arthritis	164
5.2.1.	Pyogenic sterile arthritis, pyoderma gangrenosum and acne (PAPA) syndrome	164
5.3.	With inflammatory bowel disease	164
5.3.1.	Early onset inflammatory bowel disease (EO-IBD)	164
5.4.	Without other organ manifestation	165
5.4.1.	Deficiency of interleukin 36 receptor antagonist (DITRA)	165
5.4.2.	<i>CARD14</i> mediated psoriasis (CAMPs)	165
6.	Syndromes with atypical neutrophilic dermatosis with histiocytic-like infiltrate	165
6.1.	Proteasome associated autoinflammatory syndromes (PRAAS)	165
6.1.1.	Epidemiology and genetics	165
6.1.2.	Clinical presentation and diagnosis	167
6.1.3.	Treatment	168
7.	Syndromes presenting with autoinflammation and with immunodeficiency	169
8.	Conclusion	169
	Conflict of interest statement	169
	Acknowledgments	169
	References	169

1. Introduction

The history of “autoinflammatory diseases” dates back to the identification of the genetic causes of the two most prevalent monogenic autoinflammatory diseases worldwide. Mutations in *MEFV* as the cause of familial Mediterranean fever (FMF) and mutations in *TNFRSF1A* as the cause of TNF receptor associated periodic syndrome (TRAPS) were identified in 1997 and 1999 respectively [1–3]. These discoveries have marked the beginning of an exciting journey that led not only to the molecular understanding of previously clinically defined entities, but also to the characterization of novel diseases that were not previously clinically described.

The discovery that gain of function mutations in *NLRP3*, a component of an IL-1 β processing complex, the NLRP3 inflammasome, can cause the spectrum of clinical disorders

now called cryopyrinopathies, including familial cold auto-inflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID) also called chronic infantile neurological and articular syndrome (CINCA) led to the hypothesis that the proinflammatory cytokine IL-1 β may play an important role in the pathogenesis of these disorders [4]. Early proof of concept studies with the IL-1 blocking agent anakinra (Kineret®) surprisingly showed impressive clinical responses in the patients treated. These studies not only validated the role of IL-1 blockade in these disorders, but also led to the FDA approval of now three IL-1 blocking agents for the treatment of these disorders, the long acting IL-1 blocking agents, rilonacept (Arcalyst®) and canakinumab (Ilaris®) approved in 2008 and 2009, respectively, and the short acting IL-1 inhibitor anakinra (Kineret®) in 2012.

Download English Version:

<https://daneshyari.com/en/article/3257015>

Download Persian Version:

<https://daneshyari.com/article/3257015>

[Daneshyari.com](https://daneshyari.com)